Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

ACTU

Actuate Therapeutics Inc

Dec 11 • 04:00PM ET

7.42

-0.18 -2.37 %

Healthcare • Biotechnology • USA • NASD

Peers: JNJ LLY MRNA PFE MRK REGN BNTX GILD NVAX VIR

| Held by: VTI IWM IWO VXF VTWO IWC VTWG RSSL URTY UWM

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.21	Insider Own	58.83%	Shs Outstand	23.24M	Perf Week	0.95%
Market Cap	172.47M	Forward P/E	-	EPS next Y	-1.14	Insider Trans	1.59%	Shs Float	9.57M	Perf Month	19.87%
Enterprise Value	155.95M	PEG	-	EPS next Q	-0.26	Inst Own	8.51%	Short Float	5.05%	Perf Quarter	11.24%
Income	-24.12M	P/S	-	EPS this Y	65.95%	Inst Trans	4.84%	Short Ratio	7.40	Perf Half Y	-13.82%
Sales	0.00M	P/B	15.77	EPS next Y	-2.40%	ROA	-150.86%	Short Interest	0.48M	Perf YTD	-6.78%
Book/sh	0.47	P/C	10.19	EPS next 5Y	22.97%	ROE	-296.04%	52W High	11.99 -38.12%	Perf Year	-10.17%
Cash/sh	0.73	P/FCF	-	EPS past 3/5Y	-15.08% -	ROIC	-212.67%	52W Low	5.47 35.65%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	8.11% 8.15%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-	Oper. Margin	-	ATR (14)	0.52	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	2.74	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	59.04	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	2.74	EPS Q/Q	17.34%	SMA20	9.37%	Beta	-0.31	Target Price	25.00
Payout	-	Debt/Eq	0.04	Sales Q/Q	-	SMA50	7.21%	Rel Volume	5.62	Prev Close	7.60
Employees	10	LT Debt/Eq	0.04	Earnings	Dec 03	SMA200	-2.68%	Avg Volume	65.31K	Price	7.42
IPO	Aug 13, 2024	Option/Short	No / Yes	EPS/Sales Surpr.	0.00% -	Trades		Volume	367,192	Change	-2.37%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-26-25	Initiated	B. Riley Securities	Buy	$20
Apr-22-25	Initiated	Craig Hallum	Buy	$21
Mar-17-25	Initiated	H.C. Wainwright	Buy	$20

Nov-28-25 09:55AM	How Much Upside is Left in Actuate Therapeutics, Inc. (ACTU)? Wall Street Analysts Think 214.06% (Zacks) +10.58%
Sep-22-25 08:45AM	Actuate Therapeutics Provides FDA with Updated Clinical Data Package to Support Planned Regulatory Interactions with FDA and EMA Over the Coming Months (GlobeNewswire) +6.78%
Sep-11-25 04:01PM	Actuate Therapeutics Announces Closing of $17.25 Million Public Offering of Common Stock, Including Full Exercise of Over-Allotment Option (GlobeNewswire)
Sep-10-25 08:31AM	Actuate Therapeutics Announces Pricing of $15.0 Million Public Offering of Common Stock (GlobeNewswire) -19.15%
Sep-09-25 04:07PM	Actuate Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire) +7.18%
08:45AM	Loading…
Aug-06-25 08:45AM	Actuate Therapeutics To Collaborate with Incyte Corporation and the University of Pittsburgh on Clinical Trial of Elraglusib in Combination with Retifanlimab and mFOLFIRINOX in Patients with Advanced Pancreatic Cancer (GlobeNewswire) +11.76%
Jul-17-25 08:45AM	Actuate Therapeutics Advances Clinical Program in Ewing Sarcoma After Positive Phase 1 Trial Demonstrates Complete and Partial Responses in Difficult-to-Treat Pediatric Sarcomas (GlobeNewswire)
Jun-24-25 09:15AM	Actuate Therapeutics Highlights Significant and Sustained Survival Benefit in Key Metastatic Pancreatic Cancer Patient Populations in Phase 2 Elraglusib Trial (GlobeNewswire)
Jun-20-25 08:45AM	Actuate Therapeutics Reports Positive Biomarker and Machine Learning Data from Phase 2 Elraglusib Trial in First-Line Treatment of Metastatic Pancreatic Cancer at ASCO (GlobeNewswire)
Jun-16-25 08:30AM	Actuate Therapeutics Announces Inclusion in the Russell 3000 and Russell 2000 Indexes (GlobeNewswire)
Jun-03-25 09:15AM	Actuate Therapeutics shares highlights from KOL eventon elraglusib data (TipRanks) -7.93%
Jun-02-25 09:00AM	Actuate Therapeutics Shares Highlights from KOL Event on Positive Topline Elraglusib Phase 2 Data in First-Line Treatment of Metastatic Pancreatic Cancer (GlobeNewswire) -11.01%
May-31-25 04:30PM	Actuate Therapeutics Presents Topline Elraglusib Phase 2 Data at ASCO 2025 Annual Meeting: Trial Meets Primary Endpoint of Median Overall Survival and Doubles 1-Year Survival in First-Line Treatment of Metastatic Pancreatic Cancer (GlobeNewswire)
May-22-25 05:05PM	Actuate Therapeutics Announces Details for 2025 ASCO Annual Meeting Presentation on Topline Elraglusib Phase 2 Data in First-Line Treatment of Metastatic Pancreatic Cancer (GlobeNewswire) -8.01%
May-07-25 08:00AM	Actuate Therapeutics to Host KOL Event on Topline Phase 2 Data of Elraglusib in Metastatic Pancreatic Ductal Adenocarcinoma During ASCO Annual Meeting (GlobeNewswire)
08:00AM	Loading…
May-06-25 08:00AM	Actuate Therapeutics Announces Statistically Significant Topline Results from Global Phase 2 Trial of Elraglusib in First-Line Treatment of Metastatic Pancreatic Cancer (GlobeNewswire) -6.88%
Apr-30-25 08:00AM	Actuate Therapeutics to Participate in Citizens Life Sciences Conference 2025 (GlobeNewswire)
Apr-23-25 10:24AM	Actuate to Present Elraglusib Phase 2 Topline Data at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire) +5.63%
Apr-17-25 08:00AM	Actuate to Present Promising Data on Elraglusib in Advanced Salivary Gland Carcinoma at the AACR Annual Meeting 2025 (GlobeNewswire)
Mar-27-25 04:01PM	Lantern Pharma Provides Business Updates and Fourth Quarter & Year-End 2024 Financial Results (Business Wire) -5.25%
Mar-26-25 09:15AM	Actuate Therapeutics: Looking To Make An Impact In Pancreatic Cancer (SeekingAlpha)
Feb-25-25 08:00AM	Actuate Announces Completion of Enrollment in a Phase 2 Trial of Elraglusib in Combination with FOLFIRINOX and Losartan in Patients with Previously Untreated Metastatic Pancreatic Cancer (GlobeNewswire)
Feb-06-25 08:00AM	Actuate Therapeutics to Participate in Upcoming Investor Conferences in February (GlobeNewswire) -6.56%
Jan-07-25 08:00AM	Actuate Therapeutics Receives EMA Orphan Medicinal Product Designation for Elraglusib for the Treatment of Pancreatic Cancer (GlobeNewswire)
Dec-17-24 08:28AM	Actuate Therapeutics Announces Positive Interim Phase 2 Data of Elraglusib in First Line Treatment of Metastatic Pancreatic Cancer (GlobeNewswire) -11.85%
Nov-26-24 08:00AM	Actuate Therapeutics to be Added to Russell 2000 Index (GlobeNewswire)
Nov-12-24 08:00AM	Actuate Announces FDA Rare Pediatric Disease Designation Granted to Elraglusib for Treatment of Ewing Sarcoma (GlobeNewswire)
Oct-29-24 06:39PM	Actuate to Participate in Lantern's Pharma Webinar on AI-Driven Drug Development (GlobeNewswire)
Sep-23-24 08:00AM	Actuate Announces Scientific Reports Publication on Elraglusib's Novel Immunomodulatory Mechanism of Action as a GSK-3 Inhibitor (GlobeNewswire) -8.89%
Sep-16-24 08:00AM	Actuate Announces Upcoming Presentation on Initial Data on Elraglusib in Combination with FOLFIRINOX at the AACR Special Conference on Advances in Pancreatic Cancer Research (GlobeNewswire)
08:00AM	Loading…
Sep-11-24 08:00AM	Actuate Receives FDA Orphan Drug Designation for Elraglusib for Treatment of Soft Tissue Sarcomas (GlobeNewswire)
Sep-09-24 08:00AM	Actuate Therapeutics Obtains Complete Responses and Provides Update on Clinical Trial of Elraglusib for the Treatment of Relapsed/Refractory Ewing Sarcoma (GlobeNewswire)
Sep-05-24 09:10AM	Actuate to Present at the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire)
Aug-20-24 09:00AM	Actuate Therapeutics to Ring the Nasdaq Opening Bell on Friday, August 23, 2024 (GlobeNewswire)
Aug-14-24 04:05PM	Actuate Therapeutics Announces Closing of Initial Public Offering (GlobeNewswire) +6.27%
Aug-12-24 08:27PM	Actuate Therapeutics Announces Pricing of Initial Public Offering (GlobeNewswire)
May-28-24 07:00AM	Actuate Therapeutics Files Registration Statement for Initial Public Offering (GlobeNewswire)

Actuate Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing therapeutics which target cancers and neurodegenerative diseases. It offers treatment for cancer and inflammatory diseases. It focuses on developing elraglusib. The company was founded by Andrew P. Mazar on January 16, 2015 and is headquartered in Fort Worth, TX.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Kairos Venture Partners II, L.	Affiliate	Dec 11 '25	Proposed Sale	7.60	280,000	2,128,000		Dec 11 04:22 PM
Bios Equity COF, LP	Director	Jun 27 '25	Buy	7.00	71,428	499,996	196,428	Jun 30 01:03 PM
Kreis Leslie W.	Director	Jun 27 '25	Buy	7.00	71,428	499,996	196,428	Jun 30 01:02 PM
Fletcher Aaron G.L.	Director	Jun 27 '25	Buy	7.00	71,428	499,996	196,428	Jun 30 01:01 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ACTU

Actuate Therapeutics Inc

Upgrade your FINVIZ experience